Table 1.

Clinicopathologic characteristics of breast cancer patients in recurrence status^∗1.

Variable	No recurrence (n = 220)		Recurrence (n = 34)		P
	N	%	N	%
MRE11 positive cells					0.030
≤50%	73	33.18	5	14.71
>50%	147	66.82	29	85.29
Stage					<0.001
I	88	40.00	2	5.88
II, III	132	60.00	32	94.12
Grade					0.543
1, 2	166	75.45	24	70.59
3	54	24.55	10	29.41
Age					0.007
<52 yrs	126	57.27	11	32.35
≥52 yrs	94	42.73	23	67.65
BMI (kg/m2)					0.151
<24	126	57.27	15	44.12
≥24	94	42.73	19	55.88
Tumor size (cm)					<0.001
<2.4 cm	150	68.18	11	32.35
≥2.4 cm	70	31.82	23	67.65
LN metastasis					0.003
Negative	149	67.73	14	41.18
Positive	71	32.27	20	58.82
ER					<0.001
Negative	63	28.64	20	58.82
Positive	157	71.36	14	41.18
PR					0.009
Negative	90	40.91	22	64.71
Positive	130	59.09	12	35.29
HER2 status					0.430
Negative	140	63.64	24	70.59
Positive	80	36.36	10	29.41
Triple negative					0.002
No	190	86.36	22	64.71
Yes	30	13.64	12	35.29
RT					0.021
No	91	41.36	7	20.59
Yes	129	58.64	27	79.41
CT					0.866
No	30	13.64	5	14.71
Yes	190	86.36	29	85.29
HT					0.001
No	72	32.73	21	61.76
Yes	148	67.27	13	38.24

^∗1Dataset was retrieved from our previous study [9]. MRE11: meiotic recombination 11; BMI: body mass index; LN: lymph node; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; RT: radiotherapy; CT: chemotherapy; HT: hormone therapy.